IFT Annual Meeting & Food Expo In Brief
Cantox expert advises on claim support: FDA's "competent and reliable scientific evidence" standard for structure/function claims appears less rigorous than its "significant scientific agreement" requirement for authorized or qualified disease-risk reduction claims, but is not actually so, regulatory consultant Kathy Musa-Veloso says. "Don't be deceived by this competent and reliable scientific evidence standard," she said July 19 at the Institute of Food Technologists Annual Meeting & Food Expo in Chicago. "In our view, it's really just a synonym for significant scientific agreement." Musa-Veloso, associate director of Cantox's Food & Nutrition Group, said even though industry stakeholders are surprised at the European Food Safety Authority's rejection rate for proposed nutrient claims, most structure/function claims in the U.S. likewise would be rejected (1"The Tan Sheet" June 7, 2010). FDA does not require firms to submit their products' structure/function claims for approval and clearly some product claims on the market are not substantiated. "If the food industry wants to encapsulate bioactives and claim efficacy akin to pharmaceuticals, [regulators] are expecting the same level of scientific data - robust clinical studies - which for the most part, do not exist," Musa-Veloso added during a session on health claims
Learn what's happening at the US FDA. On the go.
More from Archive
- • By
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
- • By
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
More from Pink Sheet
- • By
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
- • By
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.
- • By
To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.
